PE20230302A1 - Pld para su uso combinado en el tratamiento del coronavirus - Google Patents
Pld para su uso combinado en el tratamiento del coronavirusInfo
- Publication number
- PE20230302A1 PE20230302A1 PE2022001901A PE2022001901A PE20230302A1 PE 20230302 A1 PE20230302 A1 PE 20230302A1 PE 2022001901 A PE2022001901 A PE 2022001901A PE 2022001901 A PE2022001901 A PE 2022001901A PE 20230302 A1 PE20230302 A1 PE 20230302A1
- Authority
- PE
- Peru
- Prior art keywords
- pld
- treatment
- coronavirus
- plitidepsin
- combined use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere al tratamiento de la infeccion por coronavirus usando combinaciones de plitidepsina (PLD). La plitidepsina (PLD) es un depsipeptido ciclico originalmente aislado del tunicado marino Aplidium albicans. PLD tambien se conoce como Aplidin. PLD se encuentra actualmente en un estudio de prueba de concepto para evaluar el perfil de seguridad de PLD en pacientes con COVID-19. Se ha descubierto sorprendentemente que las combinaciones segun la presente invencion retienen la actividad y lo hacen con una toxicidad aceptable.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382152 | 2020-03-02 | ||
EP20382192 | 2020-03-13 | ||
EP20382266 | 2020-04-02 | ||
EP20382339 | 2020-04-27 | ||
EP20382815 | 2020-09-16 | ||
EP20382821 | 2020-09-17 | ||
PCT/EP2021/055131 WO2021175823A1 (en) | 2020-03-02 | 2021-03-02 | Pld for use in combination in the treatment of coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230302A1 true PE20230302A1 (es) | 2023-02-13 |
Family
ID=74758810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022001901A PE20230302A1 (es) | 2020-03-02 | 2021-03-02 | Pld para su uso combinado en el tratamiento del coronavirus |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230158103A1 (es) |
EP (1) | EP4114434A1 (es) |
JP (1) | JP2023517194A (es) |
KR (1) | KR20220150348A (es) |
CN (1) | CN115243703A (es) |
AU (1) | AU2021231521A1 (es) |
BR (1) | BR112022016653A2 (es) |
CA (1) | CA3169528A1 (es) |
CO (1) | CO2022014044A2 (es) |
IL (1) | IL296067A (es) |
MX (1) | MX2022010920A (es) |
PE (1) | PE20230302A1 (es) |
WO (1) | WO2021175823A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796177B (zh) * | 2022-06-27 | 2022-09-30 | 广州国家实验室 | 抗冠状病毒药物和应用 |
CN117618452A (zh) * | 2022-08-29 | 2024-03-01 | 山东如至生物医药科技有限公司 | 一种药物组合物及其制备方法和其在抗病毒方面的用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
-
2021
- 2021-03-02 IL IL296067A patent/IL296067A/en unknown
- 2021-03-02 KR KR1020227034273A patent/KR20220150348A/ko unknown
- 2021-03-02 JP JP2022552930A patent/JP2023517194A/ja active Pending
- 2021-03-02 MX MX2022010920A patent/MX2022010920A/es unknown
- 2021-03-02 CA CA3169528A patent/CA3169528A1/en active Pending
- 2021-03-02 US US17/908,531 patent/US20230158103A1/en active Pending
- 2021-03-02 PE PE2022001901A patent/PE20230302A1/es unknown
- 2021-03-02 WO PCT/EP2021/055131 patent/WO2021175823A1/en active Application Filing
- 2021-03-02 AU AU2021231521A patent/AU2021231521A1/en active Pending
- 2021-03-02 EP EP21708229.6A patent/EP4114434A1/en not_active Withdrawn
- 2021-03-02 BR BR112022016653A patent/BR112022016653A2/pt not_active Application Discontinuation
- 2021-03-02 CN CN202180018746.3A patent/CN115243703A/zh active Pending
-
2022
- 2022-09-30 CO CONC2022/0014044A patent/CO2022014044A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022014044A2 (es) | 2022-11-29 |
AU2021231521A1 (en) | 2022-10-06 |
CA3169528A1 (en) | 2021-09-10 |
EP4114434A1 (en) | 2023-01-11 |
WO2021175823A1 (en) | 2021-09-10 |
US20230158103A1 (en) | 2023-05-25 |
KR20220150348A (ko) | 2022-11-10 |
MX2022010920A (es) | 2022-11-30 |
CN115243703A (zh) | 2022-10-25 |
IL296067A (en) | 2022-11-01 |
JP2023517194A (ja) | 2023-04-24 |
BR112022016653A2 (pt) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230302A1 (es) | Pld para su uso combinado en el tratamiento del coronavirus | |
ECSP22061711A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
CR20170350A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
CL2021000938A1 (es) | Composiciones estables de semaglutida y usos de las mismas | |
AR104173A1 (es) | Variantes de protoxina ii y métodos de uso | |
CO2021000210A2 (es) | Apirasas solubilizadas, métodos y usos | |
CL2021002582A1 (es) | Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos | |
PE20220510A1 (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana | |
CR20220064A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
PE20231296A1 (es) | Formulaciones a largo plazo | |
CL2023003240A1 (es) | Cepas bacterianas con actividad fungicida, composiciones que las comprenden y uso de las mismas | |
CO2022008835A2 (es) | Agonistas del tlr7 | |
AR126239A1 (es) | Región 5 no traducida y región 3 no traducida no naturales y uso de estas | |
CO2022002493A2 (es) | Nanoemulsion de ácido 18p-glicirretínico | |
CL2021003317A1 (es) | Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula. | |
MX2023001301A (es) | Uso antiviral de liraglutida y gefitinib. | |
BR112022022923A2 (pt) | Composições farmacêuticas injetáveis e usos das mesmas | |
UY39257A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
CL2019003172A1 (es) | Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad. | |
AR121404A1 (es) | Uso de análogos de ciclosporina para tratar cáncer | |
CO2023013406A2 (es) | Análogos de rifamicina en combinación con vancomicina y usos de los mismos | |
CO2022015810A2 (es) | Variante de adamts13, composiciones y usos de estas |